Unlike systemically administered Radioligand Therapy (RLT), YntraDose can impart a relatively high locally-administered dose of radiation from within the tumour(s). The use of these two radiotherapeutic approaches could provide a powerful combination.
The beta radiation emitted by YntraDose’s yttrium-90 microspheres damages cancer cells, triggering an inflammatory and immunogenic response. It is well established that immunotherapy agents, such as checkpoint inhibitors, can boost this immune response and synergistically enhance the effects of radiotherapy.
BetaGlue is interested to collaborate and partner its YntraDose platform with therapeutic agents where there is synergistic potential. Contact us.